Nivolumab with chemotherapy neoadjuvant followed by nivolumab adjuvant for treating early stage non-small-cell lung cancer

Neoadjuvant nivolumab in combination with chemotherapy followed by adjuvant nivolumab is currently in clinical development for early stage non-small-cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer. Early-stage lung cancer is typically treated with surgery consisting of removing either part of or the whole of the lung, followed by chemotherapy and/or radiotherapy. However, the long-term outlook for patients undergoing this treatment pathway is still poor. Treatment with medicines prior to surgery (neoadjuvant) and after surgery (adjuvant) may provide better long term survival prospects and reduce the risk of disease recurrence for patients with resectable NSCLC.